5-羟色胺中毒综合征:现有相关综合征诊断标准的不足
本文为叙述性综述,检索1990年1月至2021年7月Embase和PubMed文献,评估Sternbach、Serotonin Syndrome Scale、Radomski和Hunter四种5-羟色胺毒性诊断标准。55例死亡病例中12例(22%)不太可能是5-羟色胺毒性;Sternbach和Radomski标准分别有25例(45%)和20例(36%)符合,10例(18%)符合排除标准,Hunter标准仅13例(24%)记录为符合、42例(76%)数据不足。作者提出诊断应同时考虑致病药物和临床情景,中高先验概率者可用Hunter标准,低概率者需更严格标准,并建议病例报告最小数据集。
要点
- 5-羟色胺毒性是临床诊断,现有4种标准中Serotonin Syndrome Scale未在5-羟色胺毒性患者中验证,仅用于使用5-羟色胺能药物者。
- 55例死亡病例中12例(22%)不太可能是5-羟色胺毒性,提示仅凭症状标准诊断易误诊。
- Sternbach和Radomski标准分别有25例(45%)和20例(36%)符合,10例(18%)符合排除标准。
- Hunter标准仅13例(24%)记录为符合,42例(76%)数据不足,难以评估其适用性。
- 诊断应先评估药物是否增加中枢5-羟色胺及有无替代诊断,中高先验概率者用Hunter标准,低概率者需更严格标准。
适用人群与场景
- 适用于急诊和中毒评估中怀疑5-羟色胺毒性的患者,包括过量服药者和使用治疗剂量5-羟色胺能药物者。
- 在选择性5-羟色胺再摄取抑制剂过量中毒中,中度5-羟色胺毒性发生率为14%;单胺氧化酶抑制剂与5-羟色胺能药物联合过量时,一半患者至少出现中度严重5-羟色胺毒性。
- 使用治疗剂量5-羟色胺能药物者中5-羟色胺毒性发生率似乎很低。
诊断标准与关键阈值
- 5-羟色胺毒性为临床诊断,特征为神经肌肉兴奋、精神状态改变和自主神经失调,症状谱从轻度到危及生命。
- 现有4种诊断标准:Sternbach、Serotonin Syndrome Scale、Radomski和Hunter标准;Serotonin Syndrome Scale未在5-羟色胺毒性患者中验证,仅用于使用5-羟色胺能药物者。
- 其余3种标准应用更广,但很少经过完善或验证。
- 作者提出:先评估致病药物和临床情景确定5-羟色胺毒性可能性;中高先验概率(如5-羟色胺能药物相互作用、过量、近期开始或增加5-羟色胺能药物剂量)者可按Hunter标准诊断;低概率(如稳定治疗剂量的5-羟色胺能药物)者需更特异和严格的标准。
红旗征与不能漏的情况
- 55例死亡病例中12例(22%)不太可能是5-羟色胺毒性,提示不能仅凭症状标准诊断,需考虑替代诊断。
- 已有病例报告和政府警告涉及不能合理引起显著5-羟色胺毒性的药物(如昂丹司琼和抗精神病药),应避免将此类药物误判为病因。
研究设计与关键结果
- 叙述性综述:检索Embase和PubMed 1990年1月至2021年7月文献,关键词为「serotonin syndrome/toxicity」配对「diagnostic criteria」或「diagnosis」,并独立评估近期系统评价中的死亡病例。
- 55例死亡病例中,12例(22%)不太可能是5-羟色胺毒性;Sternbach和Radomski标准分别有25例(45%)和20例(36%)符合;10例(18%)符合排除标准;Hunter标准仅13例(24%)记录为符合,42例(76%)数据不足。
- 在选择性5-羟色胺再摄取抑制剂过量中毒的大病例系列中,中度5-羟色胺毒性发生在14%的中毒病例;单胺氧化酶抑制剂与5-羟色胺能药物联合过量时,一半患者至少出现中度严重5-羟色胺毒性。
证据类型、等级与局限
- 证据类型:叙述性综述,基于文献检索和死亡病例评估。
- 局限:Serotonin Syndrome Scale未在5-羟色胺毒性患者中验证;其余3种标准很少经过完善或验证;死亡病例报告中Hunter标准数据不足者达42例(76%)。
对床旁实践的改变
- 作者认为,评估5-羟色胺中毒综合征时应同时考虑致病药物和临床情景,以确定5-羟色胺毒性的可能性。
- 作者提出,中高先验概率(如5-羟色胺能药物相互作用、过量、近期开始或增加5-羟色胺能药物剂量)者可基于Hunter标准诊断。
- 作者提出,低概率(如稳定治疗剂量的5-羟色胺能药物)者需要更特异和严格的标准。
- 作者建议未来更完整、准确地报告5-羟色胺毒性病例,避免进一步误导生理上不可能的关联。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Serotonin syndrome (toxicity) describes adverse drug effects from toxic amounts of intra-synaptic central nervous system serotonin. A wide range of drugs have been implicated to cause serotonin toxicity, not all justifiably. The plausible agents all have a final common pathway resulting in a substantial increase in central nervous system serotonergic neurotransmission. Serotonin toxicity is characterized by neuromuscular excitation, mental status changes, and autonomic dysregulation. Signs and symptoms represent a spectrum of toxicity (mild to life-threatening) related to increasing serotonin concentrations. As there is no consensus on the threshold for "toxicity" or diagnostic criteria, the true incidence of serotonin toxicity is unknown. The incidence in overdose is easier to quantify and is reasonably common in serotonergic antidepressant overdoses. In a large case series of overdoses, moderate serotonin toxicity occurred in 14% of poisonings with a selective serotonin reuptake inhibitor. While half those ingesting a monoamine oxidase inhibitor in combination with a serotonergic agent in overdose exhibit at least moderately severe serotonin toxicity. In contrast, the incidence of serotonin toxicity in those on therapeutic serotonergic agents appears to be very low.
OBJECTIVES: To provide a narrative review of the current diagnostic criteria, utilizing case reports of fatalities to evaluate how many meet the various diagnostic criteria and propose practical solutions to resolve controversies in diagnosis.
METHODS: A review of serotonin toxicity diagnostic criteria in the English literature was completed by searching Embase and PubMed from January 1990 to July 2021 for the keywords "serotonin syndrome/toxicity" paired with "diagnostic criteria" or "diagnosis." Also, fatal cases of serotonin toxicity identified from a recent systematic review were independently examined to determine what diagnostic criteria were met and whether serotonin toxicity or another cause was most likely.
REVIEW OF DIAGNOSIS CRITERIA: Serotonin toxicity is a clinical diagnosis, four diagnostic criteria (Sternbach, Serotonin Syndrome Scale, Radomski, and Hunter) have been proposed. However, the Serotonin Syndrome Scale has not been validated in patients with serotonin toxicity and only utilized in those on a serotonergic agent. The remaining three criteria are utilized more widely but have undergone little refinement or validation.
REVIEW OF FATAL CASES: Shortfalls with diagnostic criteria can be illustrated by examining case fatalities. Of 55 fatal cases reviewed, 12 (22%) were unlikely to be serotonin toxicity. Sternbach and Radomski criteria were met by 25 (45%), 20 (36%) had insufficient data reported and 10 (18%) met an exclusion criterion. Few had sufficient information reported to determine whether Hunter Criteria were met, with only 13 (24%) documented as meeting the criteria, the remaining 42 (76%) had insufficient data.
RESOLVING SHORTFALLS IN CURRENT DIAGNOSTIC CRITERIA: As serotonin toxicity is a clinical diagnosis, issues arise when basing the diagnosis on symptom criteria alone, without considering whether the drug/s ingested increase central nervous system serotonin or whether there is an alternative diagnosis. This has resulted in case reports and government warnings for drugs that cannot plausibly cause significant serotonin toxicity (e.g., ondansetron and antipsychotics). We propose when assessing for a serotonin toxidrome, both the causative agent(s) and clinical scenario is considered to determine the likelihood of serotonin toxicity. Then the clinical features assessed, those with a moderate to high prior probability (e.g., serotonergic drug-drug interaction, overdose, recent initiation or increase in dose of serotonergic agent/s) could be diagnosed based on the Hunter criteria. However, those with a low probability (e.g., stable therapeutic doses of a serotonergic agent) require more specific and stringent criteria. Finally, we propose a minimum dataset for case reports/series of serotonin toxicity.
CONCLUSIONS: More complete and accurate reporting of serotonin toxicity cases is required in the future, to avoid further misleading associations that are physiologically implausible.
参考来源
- Chiew AL, Buckley NA. The serotonin toxidrome: shortfalls of current diagnostic criteria for related syndromes. Clin Toxicol (Phila). 2021. PMID: 34806513. doi:10.1080/15563650.2021.1993242
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。